DE
VRTX icon

Diversified Enterprises’s Vertex Pharmaceuticals VRTX Stock Holding History

Diversified Enterprises’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$639K Sell
1,432
-175
-11% -$81.6K 0.04% 207
2025
Q4 		$729K Buy
+1,607
New +$693K 0.04% 166
2025
Q3 		– Sell
-505
Closed -$225K – 334
2025
Q2 		$225K Sell
505
-42
-8% -$19.4K 0.02% 288
2025
Q1 		$265K Buy
+547
New +$255K 0.02% 250

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Diversified Enterprises's VRTX Position: Q1 2026 in Review

Diversified Enterprises reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, selling an estimated $81.6K and leaving 1,432 shares worth $639K. The position accounts for 0.04% of the portfolio, ranked #207.

Diversified Enterprises first reported a position in VRTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $729K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Diversified Enterprises held 1,432 shares of Vertex Pharmaceuticals worth $639K as of Q1 2026.
  • Diversified Enterprises sold 175 Vertex Pharmaceuticals shares in Q1 2026, an estimated $81.6K.
  • Vertex Pharmaceuticals made up 0.04% of Diversified Enterprises's portfolio in Q1 2026, its #207 holding.
  • Diversified Enterprises first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Diversified Enterprises's Vertex Pharmaceuticals position peaked at $729K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Diversified Enterprises's 13F filing for Q1 2026, filed 15 May 2026.